ImmunoGen Performance
| IMGNDelisted Stock | USD 18.20 0.81 4.26% |
The company retains a Market Volatility (i.e., Beta) of 2.1, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ImmunoGen will likely underperform. ImmunoGen right now retains a risk of 0.0%. Please check out ImmunoGen semi variance, and the relationship between the treynor ratio and daily balance of power , to decide if ImmunoGen will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days ImmunoGen has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, ImmunoGen is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 309.5 M |
ImmunoGen |
ImmunoGen Relative Risk vs. Return Landscape
If you would invest 1,820 in ImmunoGen on September 1, 2024 and sell it today you would earn a total of 0.00 from holding ImmunoGen or generate 0.0% return on investment over 90 days. ImmunoGen is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than ImmunoGen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ImmunoGen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ImmunoGen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ImmunoGen, and traders can use it to determine the average amount a ImmunoGen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| IMGN |
Based on monthly moving average ImmunoGen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ImmunoGen by adding ImmunoGen to a well-diversified portfolio.
ImmunoGen Fundamentals Growth
ImmunoGen Stock prices reflect investors' perceptions of the future prospects and financial health of ImmunoGen, and ImmunoGen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ImmunoGen Stock performance.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0849 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 8.2 B | |||
| Shares Outstanding | 279.35 M | |||
| Price To Earning | (4.49) X | |||
| Price To Book | 15.53 X | |||
| Price To Sales | 30.33 X | |||
| Revenue | 287.61 M | |||
| EBITDA | (78.46 M) | |||
| Cash And Equivalents | 373.87 M | |||
| Cash Per Share | 1.69 X | |||
| Total Debt | 15.24 M | |||
| Debt To Equity | 0.07 % | |||
| Book Value Per Share | 2.06 X | |||
| Cash Flow From Operations | (197.89 M) | |||
| Earnings Per Share | (0.28) X | |||
| Total Asset | 348.94 M | |||
| Retained Earnings | (1.69 B) | |||
| Current Asset | 253.11 M | |||
| Current Liabilities | 60.44 M | |||
About ImmunoGen Performance
By examining ImmunoGen's fundamental ratios, stakeholders can obtain critical insights into ImmunoGen's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that ImmunoGen is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate therapies to treat cancer. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Immunogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people.Things to note about ImmunoGen performance evaluation
Checking the ongoing alerts about ImmunoGen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ImmunoGen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ImmunoGen is not yet fully synchronised with the market data | |
| ImmunoGen has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 287.61 M. Net Loss for the year was (73.52 M) with loss before overhead, payroll, taxes, and interest of (104.76 M). | |
| ImmunoGen currently holds about 373.87 M in cash with (197.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.69. | |
| Over 91.0% of the company shares are owned by institutional investors |
- Analyzing ImmunoGen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ImmunoGen's stock is overvalued or undervalued compared to its peers.
- Examining ImmunoGen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ImmunoGen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ImmunoGen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ImmunoGen's stock. These opinions can provide insight into ImmunoGen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |